Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.
BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...
The two largest leases in Boston-Cambridge's life science market went to Korro Bio and Ultragenyx Pharmaceuticals, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback